Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1.5 x 10\^8 ULSC will be added into 250 sterile saline IV bag for infusion (total volume of 260 mL volume).”In the company’s words, NCT07160205 on ClinicalTrials.gov
- Tested for
- Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS, FSHD - Facioscapulohumeral Muscular Dystrophy
- Main trialPhase 2/3
- “The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyositis (DM/PM), also known as idiopathic inflammatory myopathy (IIM) in adults. It will assess safety and efficacy in relieving symptoms of DM/PM with ULSC administered in three intravenous (IV) doses of 150 million cells per dose. The main questions that this study plans to answer are: * Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion? * Does ULSC improve symptoms of DM/PM after three doses?…”In the company’s words, NCT07160205 on ClinicalTrials.gov
Other drugs for Idiopathic Inflammatory Myositis (IIM)
- BDB-001Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
- BenralizumabAstraZeneca · Phase 3
- SHR-1703Hengrui · Phase 2/3
- IptacopanNovartis · Phase 2
- NS-229NS Pharma, Inc. · Phase 2
- TarperprumigAlexion Pharmaceuticals, Inc. · Phase 2
Coming up2
- Sep 2028Phase 2/3 trial completes · ClinicalTrials.gov
- Sep 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Sep 2028 | Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) | |
| Phase 1Recruiting | Sep 2029 | Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026